Collegium to Present at the H.C. Wainwright Global Life Sciences Conference

CANTON, Mass., April 04, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will present at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 10, 2018 at 11:55 a.m. CET at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.

About Collegium Pharmaceutical, Inc.

Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative, differentiated products for patients suffering from pain. 

About Xtampza ER

Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Contact: Alex Dasalla[email protected]

Source: Collegium Pharmaceutical, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Collegium Announces $50 Million Accelerated Share Repurchase Program
• H.C. Wainwright Reiterates Buy Rating on Cognition Therapeutics (CGTX)
• Collegium Pharmaceutical launches $50M accelerated share repurchase